pSivida in Tech Agreement with Global Pharma

pSivida Corp. has signed a funded technology evaluation agreement with a leading global pharmaceutical company that will evaluate pSivida’s Durasert and Tethadur technologies for ophthalmology products. The Durasert technology is designed to deliver specific quantities of drugs directly to a target site at controlled rates for predetermined periods of time, and the Tethadur technology is for the delivery of proteins, peptides and antibodies.
 
“We are extremely pleased to be working with another global pharmaceutical company to apply our unique technologies to develop transformational products in  ophthalmology,” said Dr. Paul Ashton, pSivida president and chief executive officer.
 
pSivida has developed three of the four sustained release devices for retinal diseases that have been approved in the U.S. and Europe. Independently, pSivida is developing an injectable, sustained release product to treat posterior uveitis, and an injectable, bioerodible product to treat glaucoma and ocular hypertension in collaboration with Pfizer.